Literature DB >> 18687747

Embolization of residual fistula following stereotactic radiosurgery in cerebral arteriovenous malformations.

T J Hodgson1, A A Kemeny, A Gholkar, N Deasy.   

Abstract

Treatment of brain arteriovenous malformations (BAVMs) often requires a multitechnique approach. We present 2 cases of BAVM, in which initial stereotactic radiosurgery (SRS) was successful in obliterating a significant volume of the nidus. At follow-up angiography, residual fistulas were identified and selectively embolized; this procedure cured the lesions. Many series describe initial embolization to reduce the nidal volume followed by SRS to the remnant. The described cases highlight the value of primary radiosurgery followed by selective fistula embolization.

Entities:  

Mesh:

Year:  2008        PMID: 18687747     DOI: 10.3174/ajnr.A1240

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  4 in total

Review 1.  Targeted endovascular treatment for ruptured brain arteriovenous malformations.

Authors:  Kun Hou; Kan Xu; Xuan Chen; Tiefeng Ji; Yunbao Guo; Jinlu Yu
Journal:  Neurosurg Rev       Date:  2019-11-13       Impact factor: 3.042

2.  Embolization and radiosurgery for arteriovenous malformations.

Authors:  Andres R Plasencia; Alejandro Santillan
Journal:  Surg Neurol Int       Date:  2012-04-26

3.  Effectiveness of Preradiosurgical Embolization with NBCA for Arteriovenous Malformations - Retrospective Outcome Analysis in a Japanese Registry of 73 Patients (J-REAL study).

Authors:  Shigeru Miyachi; Takashi Izumi; Tetsu Satow; Kittipong Srivatanakul; Yasushi Matsumoto; Tomoaki Terada; Yuji Matsumaru; Hiro Kiyosue
Journal:  Neurointervention       Date:  2017-09-05

4.  Gamma Knife Radiosurgery Followed by Flow-Reductive Embolization for Ruptured Arteriovenous Malformation.

Authors:  Myung Ji Kim; So Hee Park; Keun Young Park; Hyun Ho Jung; Jong Hee Chang; Jin Woo Chang; Jae Whan Lee; Won Seok Chang
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.